+

WO2001012664A3 - Notch receptor ligands and uses thereof - Google Patents

Notch receptor ligands and uses thereof Download PDF

Info

Publication number
WO2001012664A3
WO2001012664A3 PCT/US2000/022609 US0022609W WO0112664A3 WO 2001012664 A3 WO2001012664 A3 WO 2001012664A3 US 0022609 W US0022609 W US 0022609W WO 0112664 A3 WO0112664 A3 WO 0112664A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor ligands
notch receptor
polypeptides
enhancing
compositions
Prior art date
Application number
PCT/US2000/022609
Other languages
French (fr)
Other versions
WO2001012664A2 (en
Inventor
Chan Vivien
Michael Rohan
Lewis T Williams
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to EP00957528A priority Critical patent/EP1206487A2/en
Priority to AU69131/00A priority patent/AU6913100A/en
Priority to JP2001517562A priority patent/JP2003507029A/en
Publication of WO2001012664A2 publication Critical patent/WO2001012664A2/en
Publication of WO2001012664A3 publication Critical patent/WO2001012664A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides polynucleotides encoding two human Notch receptor ligands, encoded polypeptides, and antibodies specific to the polypeptides. Also provided are methods and compositions for enhancing or inhibiting angiogenesis as well as modulating immune responses.
PCT/US2000/022609 1999-08-19 2000-08-17 Notch receptor ligands and uses thereof WO2001012664A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00957528A EP1206487A2 (en) 1999-08-19 2000-08-17 Notch receptor ligands and uses thereof
AU69131/00A AU6913100A (en) 1999-08-19 2000-08-17 Notch receptor ligands and uses thereof
JP2001517562A JP2003507029A (en) 1999-08-19 2000-08-17 Notch receptor ligands and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14993499P 1999-08-19 1999-08-19
US60/149,934 1999-08-19

Publications (2)

Publication Number Publication Date
WO2001012664A2 WO2001012664A2 (en) 2001-02-22
WO2001012664A3 true WO2001012664A3 (en) 2002-01-10

Family

ID=22532424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022609 WO2001012664A2 (en) 1999-08-19 2000-08-17 Notch receptor ligands and uses thereof

Country Status (4)

Country Link
EP (1) EP1206487A2 (en)
JP (1) JP2003507029A (en)
AU (1) AU6913100A (en)
WO (1) WO2001012664A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518785A (en) * 2001-11-14 2005-06-30 ロランティス リミテッド Internal medicine
US8029984B2 (en) 2003-08-08 2011-10-04 Licentia, Ltd. Materials and methods for colorectal cancer screening, diagnosis and therapy
EP3342786B1 (en) 2010-01-29 2021-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
NZ628804A (en) 2012-02-24 2017-08-25 Abbvie Stemcentrx Llc Dll3 modulators and methods of use
DK2958944T3 (en) 2013-02-22 2019-06-24 Abbvie Stemcentrx Llc ANTI-DLL3 ANTISTOF PBD CONJUGATES AND USES THEREOF
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
SG11201606898TA (en) 2014-02-21 2016-09-29 Stemcentrx Inc Anti-dll3 antibodies and drug conjugates for use in melanoma
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
KR20230035138A (en) 2020-03-31 2023-03-10 추가이 세이야쿠 가부시키가이샤 Dll3-targeting multispecific antigen-binding molecules and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045434A1 (en) * 1997-04-04 1998-10-15 Millennium Biotherapeutics, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
WO1998051799A1 (en) * 1997-05-14 1998-11-19 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation inhibitor
JPH11299493A (en) * 1998-02-19 1999-11-02 Asahi Chem Ind Co Ltd Human delta-3

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045434A1 (en) * 1997-04-04 1998-10-15 Millennium Biotherapeutics, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
WO1998051799A1 (en) * 1997-05-14 1998-11-19 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation inhibitor
JPH11299493A (en) * 1998-02-19 1999-11-02 Asahi Chem Ind Co Ltd Human delta-3

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL "Human delta-1 probe", XP002167529 *
DATABASE EMBL 19 October 1997 (1997-10-19) *
DATABASE EMBL 24 March 2000 (2000-03-24) *
DATABASE EMBL 3 June 1999 (1999-06-03), ALMEIDA J., XP002157678 *
DATABASE EMBL 9 October 1998 (1998-10-09), NAKAYAMA K. ET AL., XP002157677 *
DATABASE WPI Section Ch Week 199850, Derwent World Patents Index; Class B04, AN 1998-594482, XP002157679 *
DATABASE WPI Section Ch Week 200007, Derwent World Patents Index; Class B04, AN 2000-075282, XP002157719 *
DUNWOODIE S L ET AL: "Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo.", DEVELOPMENT, (1997 AUG) 124 (16) 3065-76., XP002126914 *
GRAY G.E. ET AL: "Human ligands of the Notch receptor.", AMERICAN JOURNAL OF PATHOLOGY, (1999) 154/3 (785-794)., XP000960906 *

Also Published As

Publication number Publication date
WO2001012664A2 (en) 2001-02-22
EP1206487A2 (en) 2002-05-22
AU6913100A (en) 2001-03-13
JP2003507029A (en) 2003-02-25

Similar Documents

Publication Publication Date Title
WO1999011791A3 (en) Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO2000001815A3 (en) Neurotrophic factors
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO1999003822A8 (en) Bicyclic metabotropic glutamate receptor ligands
WO2001053455A3 (en) Novel nucleic acids and polypeptides
EP1482040A3 (en) Nl3 tie receptor tyrosine kinase ligand homologues
WO2002024909A3 (en) Receptor nucleic acids and polypeptides
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
EP1162264A3 (en) Chimeric hormone receptor
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2001012664A3 (en) Notch receptor ligands and uses thereof
WO2002066647A3 (en) Type 2 ctokine receptor and nucleic acids encoding same
GB9820003D0 (en) Novel compounds
GB9812163D0 (en) Novel compounds
GB9810285D0 (en) Novel compounds
WO2003040345A3 (en) Type 2 cytokine receptor and nucleic acids encoding same
WO2000061787A3 (en) gyrA
WO2000075321A3 (en) Polynucleotides and membrane-bound polypeptide encoded thereby
WO1999053091A3 (en) Dna coding for gdnf, parts of said dna and gdnf variants
EP1576099A3 (en) Novel polynucleotides encoding the human citron kinase polypeptide, bmsnkc 0020/0021
AU2003234717A1 (en) Novel polynucleotides encoding the human citron kinase polypeptide, bmsnkc 0020/0021
WO2001087917A8 (en) Novel nucleic acids and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000957528

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000957528

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载